Selected article for: "acute exacerbation and copd acute exacerbation"

Author: Rady, W.; Abouelela, A.; Abdallah, A.; Youssef, W.
Title: Role of bronchoscopy during non invasive ventilation in hypercapnic respiratory failure
  • Cord-id: 4gl5xe1w
  • Document date: 2014_7_22
  • ID: 4gl5xe1w
    Snippet: INTRODUCTION: Non invasive positive pressure ventilation (NIPPV) is the first line treatment for hypercapnic acute respiratory failure (ARF) secondary to COPD exacerbation in selected patients. Limited data exist supporting the use of fiberoptic bronchoscopy (FOB) during this clinical setting. The aim of this study is to assess the role of FOB during NIPPV in patients with decompensated COPD acute exacerbation. METHODS: This study is a randomized prospective case control pilot study carried out
    Document: INTRODUCTION: Non invasive positive pressure ventilation (NIPPV) is the first line treatment for hypercapnic acute respiratory failure (ARF) secondary to COPD exacerbation in selected patients. Limited data exist supporting the use of fiberoptic bronchoscopy (FOB) during this clinical setting. The aim of this study is to assess the role of FOB during NIPPV in patients with decompensated COPD acute exacerbation. METHODS: This study is a randomized prospective case control pilot study carried out on 50 patients - admitted to critical care units at Alexandria University Hospital, Egypt - suffering from hypercapnic ARF secondary to COPD exacerbation with Kelly Matthay Score from 2 to 4. All patients received NIPPV. Patients were divided randomly into 2 equal groups: group I (cases) (25 patients) was subjected to additional intervention of early FOB during the first 6–12 h from admission while group II (control) (25 patients) received the conventional treatment and NIPPV only. Outcome parameters measured were changes in ABG data, duration of NIPPV, rate of its success, ICU stay and mortality as well as the safety of FOB and possible complications. RESULTS: No significant difference was detected between the 2 groups regarding the baseline characteristics. No serious complications happened from FOB, and Oxygen desaturation happened in 4/25 patients (16%), Tachycardia in 2/25 patients (8%). In group I, 23 patients (92%) were successfully weaned from NIPPV versus 16 patients (64%) in group II (p = 0.037). Total duration of NIPPV was 28.52 h in group I versus 56.25 h in group II (p = 0.001). Length of ICU stay was 4.84 days in group I versus 8.68 days in group II (p = 0.001). Only 1 patient died in group I versus 3 patients in group II (p = 0.609). CONCLUSION: The early application of FOB during NIPPV in patients with ARF due to COPD exacerbation was shown to be safe. Significant improvement in the outcome of patients who underwent FOB was noticed in terms of improved ABG data, shorter duration of NIPPV, higher percentage of success and shorter ICU stay while no significant difference was detected in mortality.

    Search related documents:
    Co phrase search for related documents
    • accurate diagnosis and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute exacerbation and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute exacerbation and lung inflammatory response: 1
    • acute increase and lung disease: 1, 2, 3, 4, 5, 6, 7
    • acute increase and lung secretion: 1
    • acute respiratory failure and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory failure and lung inflammatory response: 1, 2, 3, 4, 5
    • acute respiratory failure patient and lung disease: 1
    • acute worsening and lung disease: 1, 2, 3, 4, 5, 6, 7
    • adenovirus coronavirus and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • adenovirus coronavirus parainfluenza and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • adenovirus coronavirus parainfluenza influenza and lung disease: 1, 2, 3, 4, 5, 6, 7
    • low molecular and lung disease: 1, 2, 3, 4, 5, 6, 7, 8
    • low molecular and lung inflammatory response: 1, 2
    • low molecular weight heparin and lung disease: 1, 2, 3
    • low molecular weight heparin and lung inflammatory response: 1